Rivaroxaban with or without aspirin in stable cardiovascular disease

Eikelboom, J. W. et al. (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. New England Journal of Medicine, 377(14), pp. 1319-1330. (doi: 10.1056/NEJMoa1709118) (PMID:28844192)

[img]
Preview
Text
147557.pdf - Published Version

373kB

Abstract

Background: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. Methods: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. Results: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=-4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. Conclusions: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events. (Funded by Bayer; COMPASS ClinicalTrials.gov number, NCT01776424 .).

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Guzik, Professor Tomasz
Authors: Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., Widimsky, P., Hori, M., Avezum, A., Piegas, L. S., Branch, K. R.H., Probstfield, J., Bhatt, D. L., Zhu, J., Liang, Y., Maggioni, A. P., Lopez-Jaramillo, P., O'Donnell, M., Kakkar, A., Fox, K. A.A., Parkhomenko, A. N., Ertl, G., Störk, S., Keltai, M., Ryden, L., Pogosova, N., Dans, A. L., Lanas, F., Commerford, P. J., Torp-Pedersen, C., Guzik, T. J., Verhamme, P. B., Vinereanu, D., Kim, J.-H., Tonkin, A. M., Lewis, B. S., Felix, C., Yusoff, K., Steg, P. G., Metsarinne, K. P., Cook Bruns, N., Misselwitz, F., Chen, E., Leong, D., and Yusuf, S.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:New England Journal of Medicine
Publisher:Massachusetts Medical Society
ISSN:0028-4793
ISSN (Online):1533-4406
Published Online:27 August 2017
Copyright Holders:Copyright © 2017 Massachusetts Medical Society
First Published:First published in New England Journal of Medicine 377(14): 1319-1330
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record